Payment overview · 2025
General Payments
$209.73
11 reported records · 7 companies
Healthcare provider profile · identity verified
James Raymond Buckner, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MARSHFIELD, MO · NPI 1407030349
Verified facts
What the public records show
CMS Open Payments records show James Raymond Buckner, D.O. received $209.73 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.27 | 22.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $41.19 | 19.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.80 | 16.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.24 | 14.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.30 | 10.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.02 | 9.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.91 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.73 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 979 | 275 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 887 | 142 |
| Alprazolam | Alprazolam | 550 | 84 |
| Lisinopril | Lisinopril | 549 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 134 |
| Gabapentin | Gabapentin | 474 | 119 |
| Oxycodone Hcl | Oxycodone Hcl | 465 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 411 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 120 |
| Furosemide | Furosemide | 372 | 118 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 344 | 119 |
| Omeprazole | Omeprazole | 342 | 103 |
| Metformin Hcl Er | Metformin Hcl | 309 | 82 |
| Potassium Chloride | Potassium Chloride | 309 | 92 |
| Losartan Potassium | Losartan Potassium | 302 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 83 |
| Tramadol Hcl | Tramadol Hcl | 283 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 245 | 71 |
| Eliquis | Apixaban | 240 | 49 |
| Famotidine | Famotidine | 233 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 59 |
| Trazodone Hcl | Trazodone Hcl | 208 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 207 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 199 | 42 |
| Pregabalin | Pregabalin | 195 | 33 |
| Clonazepam | Clonazepam | 183 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 179 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 52 |
| Montelukast Sodium | Montelukast Sodium | 167 | 38 |
| Metformin Hcl | Metformin Hcl | 163 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 47 |
| Carvedilol | Carvedilol | 150 | 39 |
| Ondansetron Odt | Ondansetron | 140 | 31 |
| Temazepam | Temazepam | 131 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 32 |
| Lorazepam | Lorazepam | 122 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 31 |
| Nitroglycerin | Nitroglycerin | 114 | 69 |
| Baclofen | Baclofen | 107 | 26 |
| Ibuprofen | Ibuprofen | 107 | 34 |
| Simvastatin | Simvastatin | 105 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 30 |
| Meloxicam | Meloxicam | 101 | 28 |
| Lovastatin | Lovastatin | 100 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 97 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 95 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 19 |
| Alendronate Sodium | Alendronate Sodium | 94 | 25 |
| Diazepam | Diazepam | 94 | 22 |
| Sertraline Hcl | Sertraline Hcl | 93 | 31 |
| Ezetimibe | Ezetimibe | 88 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 87 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 20 |
| Allopurinol | Allopurinol | 75 | 21 |
| Aripiprazole | Aripiprazole | 74 | suppressed |
| Mounjaro | Tirzepatide | 73 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 23 |
| Spironolactone | Spironolactone | 72 | 19 |
| Buspirone Hcl | Buspirone Hcl | 70 | 18 |
| Nystatin | Nystatin | 70 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 23 |
| Irbesartan | Irbesartan | 69 | 18 |
| Morphine Sulfate | Morphine Sulfate | 69 | 11 |
| Glipizide | Glipizide | 68 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 66 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 66 | 15 |
| Bupropion Xl | Bupropion Hcl | 65 | 22 |
| Glipizide Er | Glipizide | 62 | 18 |
| Ozempic | Semaglutide | 61 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 59 | 13 |
| Glimepiride | Glimepiride | 59 | 14 |
| Topiramate | Topiramate | 59 | 11 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Methocarbamol | Methocarbamol | 56 | 14 |
| Azelastine Hcl | Azelastine Hcl | 55 | 18 |
| Xtampza Er | Oxycodone Myristate | 55 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 11 |
| Finasteride | Finasteride | 53 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 11 |
| Prednisone | Prednisone | 51 | 27 |
| Propranolol Hcl | Propranolol Hcl | 50 | 13 |
| Naproxen | Naproxen | 48 | 11 |
| Jardiance | Empagliflozin | 46 | 19 |
| Celecoxib | Celecoxib | 45 | 12 |
| Atenolol | Atenolol | 44 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 16 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 16 |
| Mirtazapine | Mirtazapine | 40 | 14 |
| Naloxone Hcl | Naloxone Hcl | 40 | 34 |
| Estradiol | Estradiol | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Fentanyl | Fentanyl | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 13 |
| Sucralfate | Sucralfate | 36 | 14 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | 12 |
| Ciclopirox | Ciclopirox Olamine | 32 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 32 | suppressed |
| Ibu | Ibuprofen | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 14 |
| Ketoconazole | Ketoconazole | 31 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | 12 |
| Valsartan | Valsartan | 30 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 19 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 12 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 15 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 16 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Fetzima | Levomilnacipran Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | 13 |
| Fluconazole | Fluconazole | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Belsomra | Suvorexant | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Ramipril | Ramipril | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.73 · 11 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, JOURNAVX, Ozempic, Rybelsus, Veozah, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error